Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.31 |
| ▸ | INPP5B | P32019 | 1/20 | 0.31 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64791 | 0.86 | CYP1A2 (0.44) | CYP1A2ALPLTSHRHSD17B10KDM4E | |
| SCHEMBL5536478 | 0.82 | ELANE (0.35) | CYP1A2ALPLTSHRHSD17B10KDM4E | |
| SCHEMBL14500654 | 0.78 | TSHR (0.46) | CYP1A2ALPLTSHRHSD17B10KDM4E | |
| SCHEMBL9958029 | 0.78 | SMN1; SMN2 (0.44) | CYP1A2ALPLTSHRHSD17B10KDM4E | |
| SCHEMBL9958678 | 0.78 | CYP1A2 (0.41) | CYP1A2ALPLTSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL5702524 | 0.77 | HSD17B10 (0.41) | CYP1A2ALPLTSHRHSD17B10KDM4E | |
| SCHEMBL9958216 | 0.74 | CA12 (0.44) | CYP1A2ALPLTSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL8776805 | 0.74 | FNTA (0.39) | CYP1A2ALPLTSHRHSD17B10KDM4E | |
| SCHEMBL3839152 | 0.74 | NFE2L2 (0.42) | KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL2460830 | 0.74 | SMN1; SMN2 (0.47) | HSD17B10KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP1A2 659/4885ALPL 3589/4885TSHR 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.